Evidence map›Paper›PMID 26337656›Full record

ArticleOncotarget2015

A new phosphorylated form of Ku70 identified in resistant leukemic cells confers fast but unfaithful DNA repair in cancer cell lines.

Julien Bouley, Lina Saad, Romain Grall, Amelie Schellenbauer, Denis Biard, Vincent Paget, Sandrine Morel-Altmeyer, Olivier Guipaud, Christophe Chambon, Bernard Salles and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. The Multifaceted Roles of Ku70/80.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Julien BouleyLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Lina SaadLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Romain GrallLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Amelie SchellenbauerLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Denis BiardInstitut de Maladies Emergentes et des Thérapies Innovantes (iMETI), Service d'Etude des Prions et des Infections Atypiques (SEPIA), CEA, 92265 Fontenay aux Roses, France.
Vincent PagetLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Sandrine Morel-AltmeyerLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Olivier GuipaudLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Christophe ChambonService de Spectrométrie de Masse, INRA Theix, 63122 St Genès Champanelle, France.
Bernard SallesUMR 1331 TOXALIM, INRA/INP/UPS, F-31027 Toulouse, France.
Karim MaloumService d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, 75000 Paris, France.
Hélène Merle-BéralService d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, 75000 Paris, France.
Sylvie ChevillardLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Jozo DelicLaboratoire de Cancérologie Expérimentale, Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), 92265 Fontenay aux Roses, France.
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · FRCEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRInfectious Disease Models and Innovative Therapies · FRInstitut de Radiobiologie Cellulaire et Moléculaire · FRPitié-Salpêtrière Hospital · FRSorbonne Université · FRToxalim Research Centre in Food Toxicology · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ku70-dependent canonical nonhomologous end-joining (c-NHEJ) DNA repair system is fundamental to the genome maintenance and B-cell lineage. c-NHEJ is upregulated and error-prone in incurable forms of chronic lymphocytic leukemia which also displays telomere dysfunction, multiple chromosomal aberrations and the resistance to DNA damage-induced apoptosis. We identify in these cells a novel DNA damage inducible form of phospho-Ku70. In vitro in different cancer cell lines, Ku70 phosphorylation occurs in a heterodimer Ku70/Ku80 complex within minutes of genotoxic stress, necessitating its interaction with DNA damage-induced kinase pS2056-DNA-PKcs and/or pS1981-ATM. The mutagenic effects of phospho-Ku70 are documented by a defective S/G2 checkpoint, accelerated disappearance of γ-H2AX foci and kinetics of DNA repair resulting in an increased level of genotoxic stress-induced chromosomal aberrations. Together, these data unveil an involvement of phospho-Ku70 in fast but inaccurate DNA repair; a new paradigm linked to both the deregulation of c-NHEJ and the resistance of malignant cells.

Indexed as

Antigens, NuclearBlotting, WesternCell Line, TumorComet AssayDNA-Binding ProteinsDNA End-Joining RepairDNA RepairDrug Resistance, NeoplasmElectrophoresis, Gel, Two-DimensionalFlow CytometryFluorescent Antibody TechniqueHumansImmunoprecipitationKu AutoantigenLeukemia, Lymphocytic, Chronic, B-CellMass SpectrometryAntigens, NuclearDNA-Binding ProteinsKu AutoantigenProtein IsoformsRNA, Small InterferingXrcc6 protein, humanCLLc-NHEJDNA repair kineticgamma-H2AX/ATM/DNA-PKcsphospho-Ku70

Identifiers

PMID26337656
PMCPMC4695039
OpenAlexW2130776990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.